Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05763264
Other study ID # SAGCS2 Protocol 2.3 + Amend 1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 12, 2020
Est. completion date December 30, 2021

Study information

Verified date February 2023
Source Sagami Rubber Industries Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical study will compare two lubricated polyurethane male condoms of different thickness with a marketed lubricated control male condom made of natural rubber latex. This crossover study will randomize 300 heterosexual couples to the sequence in which they use five condoms of each of the three study condom types. The clinical failure (breakage and slippage) rates of the two polyurethane condoms will be compared to the clinical failure (breakage and slippage) rate of commercial natural rubber latex control condom using a statistical test of non-inferiority. The study will also compare the acceptability of the two polyurethane condom different thickness with that of the natural rubber latex control condom obtained from interviews and questionnaires with subject couples.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date December 30, 2021
Est. primary completion date December 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Between the ages of 18 and 45 (inclusive) 2. Protected against pregnancy by oral contraceptives, an IUD, an implant, contraceptive injections, contraceptive patch, or sterilization (tubal ligation or vasectomy) 3. Have home internet access, a valid personal email for each partner, ability to videoconference and use electronic signature technology 4. Willing and able to give electronic informed consent 5. Willing to respond to questions concerning their reproductive and contraceptive history and use of condoms via interview or self-administered questionnaires 6. Have vaginal intercourse at least once weekly 7. Willing to use the study products for fifteen acts of vaginal intercourse within nine weeks of study entry 8. In a mutually exclusive monogamous relationship with their study partner for at least 6 months and be willing to remain mutually monogamous throughout study participation 9. Both study partners have previous experience using male condoms 10. Agree not to use any additional vaginal or sexual lubricant except the AstroglideTM product provided, if desired, supplied by the study 11. Agree not to expose the study condoms to jewelry (hand, facial, or genital) or piercings (facial or genital) that could damage the study condoms. 12. Agree not to use sex toys or drugs intended to enhance or diminish sexual response when using study condoms 13. Male partner agrees to ejaculate during vaginal intercourse 14. Agree to (or partner) hold the condom at the base of the erect penis during withdrawal 15. Agree to return any condoms that break during use 16. Agree to return any unopened condoms 17. Reachable by telephone Exclusion Criteria: 1. Currently participating in another similar clinical study 2. Female partner self-reported as pregnant 3. Allergic to natural rubber latex or polyurethane, or has a history of recurrent adverse events following use of latex or polyurethane products 4. Unable to follow study requirements, use instructions or attend study visits or exchanges 5. Have a significant (high) risk of STIs, including HIV infection, or having a medical history of recurrent, uncontrolled STIs (e.g. gonorrhoea, syphilis, Chlamydia, etc.) 6. Currently using condoms for protection against a known STI 7. Taking any internally applied medication to treat a genital condition that could interact with the study condom 8. Male partner has used medication that has caused erectile dysfunction, or had difficulty achieving/maintaining an erection, or achieving ejaculation in the last month under typical circumstances/conditions 9. Male has had a prostatectomy 10. Any self-reported genitourinary condition (e.g. itching, burning, irritation, etc.) which, in the opinion of the investigator, could affect use of the study condoms or the ability to interpret study data 11. Employee or affiliate of Essential Access Health or Sagami Rubber Industries Co., Ltd.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Condom functionality study to determine failure rates

Locations

Country Name City State
United States Essential Access Health Los Angeles California

Sponsors (2)

Lead Sponsor Collaborator
Sagami Rubber Industries Co., Ltd. Essential Access Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To Confirm Non Inferiority of Experimental Condoms verses Control Condom with Respect to Clinical Failure Rates (Combined Breakage and Slippage) as per ISO 29943-1:2017. To confirm each experimental condom is non-inferior to the control condom with respect to total clinical failure rate. The definition of total clinical failure rate as specified in ISO 29943-1:2017 will be used. The Total Clinical Failure Rate is Defined as the Number of Condoms with at least One Acute Failure Event (e.g. Clinical Breakage or Clinical Slippage) Divided by the Number of Condoms Used During Intercourse; Typically Reported as a Percentage; Any Condom which Experiences Multiple Clinical Failure Events Only Count as a Single Clinical Failure. Self Completion of Questionnaires Within 12 Hours of Use.
Secondary Acceptability Measures Acceptability Evaluation by Comparing Physical Attributes and Perceptions about Each Condom Type Using a Linear Scale Ranging from 1. Strongly Agree to 7. Strongly Agree. Self Completion of Questionnaires Within 12 Hours of Use.
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A